News headlines about Akebia Therapeutics (NASDAQ:AKBA) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.1784598345545 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $14.71 on Monday. The company has a market cap of $695.33, a PE ratio of -4.66 and a beta of 0.87. Akebia Therapeutics has a 1 year low of $8.58 and a 1 year high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.07. The business had revenue of $41.28 million during the quarter, compared to analyst estimates of $34.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. analysts anticipate that Akebia Therapeutics will post -2.25 EPS for the current fiscal year.

Several research analysts have issued reports on the stock. Piper Jaffray Companies assumed coverage on shares of Akebia Therapeutics in a report on Monday, December 18th. They set an “overweight” rating and a $26.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, November 15th. Zacks Investment Research cut shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Mizuho reiterated a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a report on Thursday, November 9th. Finally, BTIG Research assumed coverage on shares of Akebia Therapeutics in a report on Thursday, December 7th. They set a “buy” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $22.20.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Akebia Therapeutics (AKBA) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-akebia-therapeutics-akba-stock-price/1818088.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.